|
Company* (Country; Symbol) |
Company* (Country; Symbol) |
Type/Product Area | Terms/Details (Date) |
| 4SC AG (Germany; FSE:VSC) | AiCuris GmbH & Co. KG* (Germany) | Research collaboration to develop a product pipeline of anti-infective drug candidates | 4SC AG will provide resources from its medicinal chemistry to AiCuris, and in return 4SC will receive unspecified research funds to further develop its own project pipeline (2/5) |
| Acceleron Pharma Inc.* | Celgene Corp. (CELG) | Partnership for the Phase I bone-forming agent ACE-011 and up to three discovery programs targeting bone loss | Potential value is $1.8B, including a $50M up-front payment, $510M in milestones for development and commercialization of ACE-011 and up to $437M in milestones for each of the three discovery programs (2/20) |
| Acorda Therapeutics Inc. (ACOR) | Neurorecovery Inc.* | Licensing and research agreements related to the use of aminopyridines in peripheral neuropathies and to two early stage development candidates | Acorda also acquired NeuroRecovery's preclinical and clinical data, regulatory filings, copyrights, trademarks and domain names relating to the three products (2/4) |
| Alexza Pharmaceuticals Inc. (ALXA) | Endo Pharmaceuticals Holdings Inc. (ENDP) | Licensing agreement that gives Endo rights to its inhaled fentanyl product, AZ-003, which is in Phase I development for break-through pain | It allows Endo to exclusively develop and commercialize the product in North America; Alexza is receiving $10M up front and could receive up to an additional $40M, as well as royalties on product sales (12/28) |
| AlgoNomics NV* (Belgium) | Genmab A/S (Denmark; CSE:GEN) | Research collaboration in which AlgoNomics will use its antibody structure database and Tripole technology to aid Genmab in research related to the structural analysis of Genmab's antibody scaffolds, including the UniBody technology | Financial terms were not disclosed (2/1) |
| Altor BioScience Corp.* | Genentech Inc. (NYSE:DNA) | Licensing agreement for exclusive worldwide rights to a class of antibody-based tissue factor antagonists | Financial terms were not disclosed (2/12) |
| Angiotech Pharmaceuticals Inc. (Canada; ANPI) | Symphony Medical Inc.* | Exclusive licensing agreement to employ one of Angiotech's PEG-based biomaterials as part of a prophylactic therapy to mitigate the onset of post-operative atrial fibrillation for patients under-going coronary artery bypass grafting and cardiac valve surgeries | Angiotech receives an equity position in Symphony Medical in exchange for the exclusive license in the field of POAF (1/18) |
| Anthera Pharmaceuticals Inc.* | Amgen Inc. (AMGN) | Licensing agreement for exclusive worldwide rights to AMG 623, a peptide fusion protein, in systemic lupus erythematosus and other autoimmune diseases | Financial terms were not disclosed (1/8) |
| Applera Corp. (NYSE:ABI) | Geisinger Health System* | Research collaboration to develop a diagnostic assay for the increased risk of non-alcoholic steatohepatitis | The collaboration will evaluate Celera's genetic findings in liver diseases; financial terms of the multiyear collaboration were not disclosed (2/19) |
| Argenta Discovery Ltd.* (UK) | NeuroSolutions Ltd.* (UK) | Alliance to gain preferential access to its specialist electro-physiology and hERG testing services and expertise | The collaboration will enable Argenta to provide its contract research clients with an expanded assay development and screening resource (1/7) |
| Artes Biotechnology GmbH* (Germany) | Rhein Minapharm Biogenetics* (unit of Minapharm SAE; Egypt) | Collaboration to develop three therapeutic proteins | Artes will use its Hansenula technology platform and know-how for the generation of cell line production, analytical assay development and lab-scale fermentation, and granted Minapharm a commercial license option to apply its technologies to the manufacturing and marketing of those proteins (1/14) |
| Bioceros BV* (the Netherlands) | MaimoniDex RA* (Israel) | Collaboration to develop a monoclonal antibody specific for CD44vRA, which is involved in the inflammatory process underlying rheumatoid arthritis | Bioceros will receive an option to a worldwide exclusive license on the intellectual property and technology owned by MaimoniDex (1/7) |
| BioCurex (Canada; OTC BB:BOCX) | Inverness Medical Innovations (AMEX:IMA) | Licensing agreement for BioCurex's RECAF material and technology | Inverness will obtain semiexclusive worldwide rights to commercialize products using the technology, and BioCurex will be paid up-front fees, product and development milestones plus royalties (1/9) |
| Biovest International Inc. (OTC BB: BVTI) | Accentia Bio-pharmaceuticals Inc. (ABPI) | Exclusive worldwide license agreement for the autoimmune disease drug Revimmune to treat and prevent transplant rejection | Biovest acquired the license from its parent company, Accentia (1/22) |
| Catalyst Biosciences Inc.* | Centocor Inc. (unit of Johnson & Johnson) | Discovery and development collaboration to create engineered protease drugs against two disease targets | Catalyst will get $11M up front, made up of cash and an equity investment, plus research funding for two years; one area is focused on inflammatory disease and the other is undisclosed (1/7) |
| Cell Signaling Technology Inc.* | TTP LabTech Ltd.* | Assay development partnership deal with custom automation and laboratory instrumentation company TTP LabTech | CST will develop and validate antibodies on TTPLT's Acumen Explorer/X3 microplate cytometric platform (1/31) |
| Crucell NV (the Netherlands; CRXL) | ISU Abxis* (South Korea) | Nonexclusive license granting ISU rights to its STAR research technology | The deal covers both a research evaluation of STAR for the production of recombinant proteins and an option for a commercial license (1/14) |
| Cryo-Cell International Inc. (OTC BB:CCEL) | Saneron CCEL Therapeutics Inc.* | Research and development agreement under which Saneron will collaborate on research involving C'elle stem cells that are derived from menstrual flow | The stem cells have many properties and characteristics similar to those of both bone marrow and embryonic stem cells (1/29) |
| DermTech Inc.* | Stiefel Laboratories Inc.* | Agreement to use DermTech's EGIR technology and gene expression assays to identify and further understand the genes involved in causing acne | DermTech will provide Stiefel its EGIR skin sampling technology consisting of adhesives that will be applied to the patients' epidermis (1/7) |
| Dynogen Pharmaceuticals Inc.* | Arachnova Therapeutics Ltd.* (UK) | Agreement for Dynogen to acquire a suite of patents relating to DDP225 for functional bowel disorders, genitourinary disorders and pain | Terms were not disclosed (1/16) |
| Eden Biodesign Ltd. (UK; EDEN) | iQur Ltd.* (UK) | Agreement to develop iQur's, tandem core vaccine for hepatitis A and B | Eden will develop a biomanufacturing process and carry out GMP manufacture for clinical trials (2/6**) |
| Epigenomics AG (Germany; BE:ECX) | Quest Diagnostics Inc. (NYSE:DGX) | Nonexclusive licensing deal for Epigenomics' DNA methy-lation biomarker Septin 9 | Quest gains rights to use the biomarker to develop a molecular-based laboratory test aimed at helping physicians detect colorectal cancer based on a patient's blood specimen (2/19) |
| Exelgen Ltd. (subsidiary of Commonwealth Biotechnologies Inc.; CBTE; UK) | Two undisclosed European biotech firms | Collaborations involving a range of research activities using Exelgen's chemistry process, including medicinal chemistry and application of its LeadHopping technology to identify and progress lead compound series into preclinical studies | Financial terms were not disclosed (12/27) |
| Genizon BioSciences Inc.* (Canada) | London Genetics Ltd.* (UK) | Collaboration to replicate discoveries made by Genizon in a genomewide association study of schizophrenia | Financial terms were not disclosed (2/8) |
| Geron Corp. (GERN) | Sienna Cancer Diagnostics* (Australia) | Licensing agreement giving Sienna access to patents and information related to the detection or measurement of telomerase activity | Sienna gains worldwide exclusive rights within a defined field to Geron-controlled intellectual property to detect telomerase activity for the cancer in vitro diagnostics market; Geron received an undisclosed equity interest in Sienna and is entitled to receive royalties on future product sales (1/24) |
| Helix BioPharma Corp. (Canada; FSE:HBP) | KBI BioPharma Inc.* | Collaboration to develop a process for preparing L-DOS47 in a freeze-dried powder format that can be stored for use in clinical trials | L-DOS47 is an antibody-based cancer drug that targets urease (1/17) |
| Human Genome Sciences Inc. (HGSI) | Aegera Therapeutics Inc.* | Agreement to develop and commercialize cancer cell-killing molecules | The three-year research deal includes an up-front fee of $15M in return for exclusive worldwide rights, excluding Japan, to AEG40826 and related backup compounds; it also could bring Aegera $295M in future development and commercial milestone payments, including a $5M milestone payment once AEG40826 gains FDA clearance for clinical trials; Aegera also may receive double-digit royalties on net sales outside of Japan; it also has the option to copromote products in North America, under which it will share 30% of expenses and 30% of profits in lieu of royalties (12/20) |
| Human Genome Sciences Inc. (HGSI) | Xencor Inc.* | Collaboration under which Xencor will apply its XmAb humanization and optimiz-ation technologies to enhance monoclonal antibodies developed by HGS that specifically target antigens discovered by HGS | Xencor will receive an up-front payment and is eligible to receive additional payments for development and commercial milestones, as well as royalties on any products commercialized (2/7) |
| ImmuneRegen BioSciences (subsidiary of IR BioSciences Holdings Inc.; IRBO) | HemoGenix* | Agreement under which HemoGenix will test Homspera and explore its potential to stimulate hematopoietic stem cell proliferation and differentiation using its ATP bioluminescence technology | Further details were not disclosed (1/28) |
| ImmunoGen Inc. (IMGN) | Centocor Inc. (unit of Johnson & Johnson) | Agreement to develop and sell preclinical IMGN388 for cancer | The deal includes no up-front money; J&J agreed to an arrangement that allows for later opt-in, ahead of a pivotal study; if it takes the option, the two firms will split development costs and profits with ImmunoGen getting royalties; otherwise, ImmunoGen could get up to $30M in milestones, plus royalties (1/3) |
| Inspiration Bio-pharmaceuticals Inc.* | Celtic Pharmaceutical Holdings LP* | Agreement for a recombinant Factor IX product for hemophilia B | Celtic will make a “modest“ equity investment in Inspiration, but the majority of the $35M deal will support development of IB1001 (1/9) |
| Isis Pharmaceuticals Inc. (ISIS) | Genzyme Corp. (GENZ) | Partnership for the Phase III lipid-lowering drug mipomersen (formerly ISIS 301012) | Genzyme is paying $325M up front, $175M in cash and $150M in equity; the equity component calls for Genzyme to buy 5M shares of Isis at $30 each; Isis also stands to get $1.575B in milestone payments, of which $825M are tied to development and approvals and $750M are tied to commercialization; Isis would get 30% of the profits; the figure would increase to 50% as mipomersen annual revenues reach $2B (1/8) |
| Karo Bio (Sweden; SSE:KARO) | Zylus Cadila* (India) | Three-year collaboration to develop new drugs for the treatment of inflammatory diseases | The goal is selective glucocorticoid receptor modulators for conditions such as rheumatoid arthritis, bowel disorders, psoriasis and asthma (2/4) |
| Lab21* (UK) | Celera (NYSE:CRA) | License agreement for access to Celera's test for cirrhosis risk in patients with chronic hepatitis C viral infection in the UK and Ireland | The test, known as CRS7, is the first clinical test capable of predicting the likelihood of an HCV patient's risk of progressing to liver fibrosis and cirrhosis (2/21) |
| Molecular Partners AG* (Switzerland) | Centocor Inc. (subsidiary of Johnson & Johnson) | Research and license agreement for applying ankyrin repeat protein technology to identify new proteins that bind to two undisclosed inflammatory disease targets | Centocor will have exclusive worldwide rights to develop and commercialize the proteins in exchange for making milestone and royalty payments to Molecular Partners (1/15) |
| NextGen Bioscience Inc. (UK; OTC BB:NXGB) | SymbioTec GmbH* (Germany) | Letter of intent to enter a collaboration based on SymbioTec's cancer drug Oncohist | Financial terms were not disclosed (2/21) |
| OncoMethylome Sciences SA (Belgium; BR:ONCOB) | Epigenomics AG (Germany; BE:ECX) | Broad technology licensing agreement under which OncoMethylome obtained worldwide nonexclusive rights to several of Epigenomics' core technologies, including its MethyLight portfolio for the detection of DNA methylation for in vitro diagnostic product development and commercialization | Epigenomics will receive an up-front payment and is eligible for royalties (1/14) |
| OncoMethylome Sciences SA (Belgium; BR:ONCOB) | Signatures Diagnostics* (Germany) | Agreement to launch a large, international, multicenter colorectal cancer clinical trial, with the German portion managed by Signatures Diagnostics | Signature will receive an up-front payment plus service fees; OncoMethylome will obtain first negotiation rights on a test in development by Signature for predicting outcomes in colorectal cancer patients; OncoMethylome also agreed to acquire a minority interest in Signature Diagnostics (1/30) |
| Ophthotech Corp.* | PDL BioPharma Inc. (PDLI) | Licensing deal to develop volociximab for use in age-related macular degeneration | PDL is entitled to undisclosed development milestone payments and royalties on product sales (1/8) |
| PDL BioPharma (PDLI) | EKR Therapeutics Inc.* | Agreement for a suite of cardiovascular products including Cardene I.V., Cardene SR and new formulations of Cardine in development, as well as Retavase and the development product ularitide | PDL will receive cash payments of $85M at closing, up to an additional $85M in development and sales milestones for the new Cardene formulations, as well as royalties on sales of the new Cardene formulations and ularitide (2/5) |
| Plexera Bioscience LLC* | Auguron Biosciences Inc.* | Option agreement giving Plexera exclusive access to use Auguron's Nucleic Acid Programmable Protein Array technology on the Plexera Kx Array Platform | The technology enables fresh, functional proteins to be generated on high-density microchips from surface printed DNA (1/30) |
| Rubicon Genomics Inc.* | OncoMethylome Sciences (Belgium; BR:ONCOB) | Collaboration to identify biomarkers for early detection of cancer | Rubicon will use its MethylPlex platform to carry out the marker identification analysis and granted an option to Onco-Methylome to license markers resulting from the collaboration (1/22) |
| Senexis Ltd.* (UK) | Oxygen Healthcare Ltd.* (UK) | Collaboration to provide synthetic and computational chemistry services for Senexis' drug discovery programs | Financial terms were not disclosed (2/14) |
| Sepracor Inc. (SEPR) | Bial SA* (Portugal) | Agreement to develop and commercialize BIA 2-093 (eslicarbazepine acetate) as a therapy to control epileptic seizures | The deal is potentially worth $175M, including an up-front payment of $75M and $100M in milestones; Sepracor gains rights in the U.S. and Canada (1/2) |
| SkyePharma plc (UK; SKYE) | Dr. Reddy's Laboratories (India; NYSE:RDY) | Agreement to undertake a feasibility study of a product using two of SkyePharma's drug delivery systems | Dr. Reddy's will pay the cost of the study and also will pay SkyePharma an up-front fee (2/8) |
| Synvista Therapeutics Inc. (AMEX:SYI) | Novel Therapeutics Technologies Inc.* | Agreement to conduct formulation work for a topical cream formulation of ALT-2074 in psoriasis | Synvista is developing ALT-2074 in cardio-vascular disease (1/17) |
| Sysmex Corp. (Japan; PK:SSMXF) | bioMerieux (France; PARIS:BIM) | Agreement under which Sysmex will take a 34% equity stake in bioMerieux's Japanese subsidiary to form a new company called Sysmex bioMerieux' Co. Ltd. | The new firm will promote and commercialize the entire bioMerieux product range in Japan starting April 1; the joint venture will take care of regulatory filings and marketing activities in Japan, while sales and customer service activities will be contracted to Sysmex (1/10) |
| Thallion Pharmaceuticals Inc.(Canada; TSX:TLN) | Expergen Drug Development GmbH* | Agreement to drop legal actions concerning the Phase II cancer drug | Thallion will pay up to C$418,880 ($414,733) in up-front and milestone-based payments, plus 150,000 common shares (1/17) |
| ZymeQuest Inc.* | Undisclosed publicly traded U.S. life sciences company | Exclusive worldwide agreement to license certain patent applications associated with its enzyme-conversion technology | ZymeQuest retains all rights to develop products related to transfusion medicine; terms call for ZymeQuest to receive an initial licensing fee of $2M, plus royalties based on production levels of products made using the technology (1/2) |
|
Notes: * Private companies are indicated with an asterisk; ** Denotes the date the item ran in BioWorld International. Unless otherwise notes, the trading symbols listed for public biotechnology companies are on the Nasdaq market.AMEX = American Stock Exchange; BE = Berlin Stock Exchange; BR = Brussels Stock Exchange; CSE - Copenhagen Stock Exchange; FSE = Frankfurt Stock Exchange; NYSE = New York Stock Exchange; OTC BB = Over-the-Counter Bulletin Board; PK = Pink Sheets; SSE = Stockholm Stock Exchange; TSX = Toronto Stock Exchange. | |||
To read more on related topics, click on one of the words below.